Výsledky vyhledávání - "Torben Straight Nissen"

Abstract 3256: RTX-IL-12, an allogeneic red cell therapeutic expressing IL-12, exhibits potent in vitro and in vivo activity and favorable safety profile

Autor: Anne-Sophie Dugast, Enping Hong, Maegan Hoover, Arjun Bollampalli, Douglas C. McLaughlin, Omkar Bhate, Timothy J. Lyford, Torben Straight Nissen, Christopher L. Carpenter, Thomas J. Wickham, Sivan Elloul

Publikováno v: Cancer Research. 79:3256-3256

Recombinant IL-12 is a potent cytokine that has held significant promise as an immunotherapeutic. In preclinical studies, recombinant IL-12 has impressive anti-tumor activity; however toxicity and a narrow therapeutic window halted development in hum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b22f405d617a0e68ea13cd287d2540b
https://doi.org/10.1158/1538-7445.am2019-3256

Zobrazit plný text záznamu

Abstract 3260: Engineered red-cell therapeutics (RCT) as artificial antigen presenting cells promotein vivoexpansion and anti-tumor activity of antigen specific T cells

Autor: Tiffany F. Chen, Shamael R. Dastagir, Naren Subbiah, Xuqing Zhang, Mengyao Luo, Christopher L. Carpenter, Nicholas Bayhi, Torben Straight Nissen, Vikram Soman, Sneha Pawar, Douglas C. McLaughlin, Viral Amin, Thomas Wickham

Publikováno v: Cancer Research. 79:3260-3260

T cell-based therapies have demonstrated efficacy in a small subset of cancers; however, they have the potential to proliferate uncontrollably and manufacturing these therapies at scale has proven difficult. To address this limitation, Rubius Therape

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::533c48c7b4d8bcca5ed46b1b87b6ff0d
https://doi.org/10.1158/1538-7445.am2019-3260

Zobrazit plný text záznamu

Abstract 3272: RTX-212, an allogeneic red cell therapeutic expressing 4-1BBL and IL-15TP, exhibits potent in vitro and in vivo activity and a favorable safety profile

Autor: Thomas Wickham, Jennifer Mellen, Shannon McArdel, Enping Hong, Maegan Hoover, Sivan Elloul, Torben Straight Nissen, Anne-Sophie Dugast, Douglas C. McLaughlin, Shannon C. Leonard, Christopher L. Carpenter, Arjun Bollampalli

Publikováno v: Cancer Research. 79:3272-3272

Recombinant agonists that activate co-stimulatory and cytokine receptors have shown limited clinical activity perhaps due to 1) toxicity; 2) a need for coordinated activation of co-stimulatory and cytokine pathways; or 3) the failure of agonist antib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f1f3863c0ab3c68b0f1acedafbde673d
https://doi.org/10.1158/1538-7445.am2019-3272

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání